|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002871,
umls-concept:C0014822,
umls-concept:C0018787,
umls-concept:C0018801,
umls-concept:C0019993,
umls-concept:C0035078,
umls-concept:C0205082,
umls-concept:C0302583,
umls-concept:C0332325,
umls-concept:C0348016,
umls-concept:C0392756,
umls-concept:C0449258,
umls-concept:C0522501,
umls-concept:C1292733,
umls-concept:C1947976
|
|
pubmed:dateCreated |
2002-9-13
|
|
pubmed:abstractText |
Both Congestive Heart Failure (CHF) and Chronic Renal Failure (CRF) are increasing steadily in the community. We propose that there is a vicious circle established whereby CHF and CRF both cause anemia and the anemia then worsens both the CHF and CRF causing more anemia and so on. We call this the Cardio Renal Anemia (CRA) syndrome. By the combination of active treatment of the CHF and control of the anemia with subcutaneous erythropoietin and intravenous iron, the progression of both the CHF and the CRF can be slowed or stopped in most cases, the quality of life improved and the need for recurrent hospitalization reduced. This will involve cooperation between internists, cardiologists, and nephrologists to allow early and maximal therapy of both the CHF and the anemia.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0301-0430
|
|
pubmed:author |
pubmed-author:BaruchRR,
pubmed-author:BlumMM,
pubmed-author:IainaAA,
pubmed-author:KerenGG,
pubmed-author:SchwartzDD,
pubmed-author:ShakedMM,
pubmed-author:ShepsDD,
pubmed-author:SilverbergD SDS,
pubmed-author:SteinbruchSS,
pubmed-author:TchebinerJJ,
pubmed-author:WexlerDD,
pubmed-author:YachninTT,
pubmed-author:ZubkovAA
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
58 Suppl 1
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
S37-45
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12227725-Aged,
pubmed-meshheading:12227725-Anemia,
pubmed-meshheading:12227725-Disease Progression,
pubmed-meshheading:12227725-Drug Therapy, Combination,
pubmed-meshheading:12227725-Erythropoietin,
pubmed-meshheading:12227725-Female,
pubmed-meshheading:12227725-Ferric Compounds,
pubmed-meshheading:12227725-Heart Failure,
pubmed-meshheading:12227725-Hospitalization,
pubmed-meshheading:12227725-Humans,
pubmed-meshheading:12227725-Injections, Intravenous,
pubmed-meshheading:12227725-Injections, Subcutaneous,
pubmed-meshheading:12227725-Kidney Failure, Chronic,
pubmed-meshheading:12227725-Male,
pubmed-meshheading:12227725-Oxygen Consumption,
pubmed-meshheading:12227725-Recombinant Proteins,
pubmed-meshheading:12227725-Stroke Volume
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization.
|
|
pubmed:affiliation |
Department of Nephrology and Cardiology, Tel Aviv Medical Center, Israel. donald@netvision.net.il
|
|
pubmed:publicationType |
Journal Article
|
